Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations

Ítems similars

• The optimal therapy strategy for epidermal growth factor receptor‐mutated non‐small cell lung cancer patients with brain metastasis: A real‐world study from Taiwan
  per: Wen‐Chien Cheng, et al.
  Publicat: (2022-05-01)
• Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma
  per: Chen, Hung-Jen, et al.
  Publicat: (2020)
• Endobronchial Ultrasound Changed the World of Lung Cancer Patients: A 11-Year Institutional Experience
  per: Chen, Chia-Hung, et al.
  Publicat: (2015)
• Interventional pulmonology for patients with central airway obstruction: An 8-year institutional experience
  per: Chen, Chia-Hung, et al.
  Publicat: (2017)
• When to Use Initial Triple Therapy in COPD: Adding a LAMA to ICS/LABA by Clinically Important Deterioration Assessment
  per: Cheng, Wen-Chien, et al.
  Publicat: (2020)